8-K 1 genelabs8k.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 16, 2003 Date of Report (Date of earliest event reported) GENELABS TECHNOLOGIES, INC. (Exact name of registrant as specified in charter) California (State or other jurisdiction of incorporation) 0-19222 94-3010150 (Commission File Number) (IRS Employer Identification No.) 505 Penobscot Drive Redwood City, California 94063 (Address of principal executive offices) (Zip Code) (650) 369-9500 (Registrant's telephone number, including area code) Item 5. Other Events and Regulation FD Disclosure. On October 16, 2003, Genelabs Technologies, Inc. (the "Company") entered into an Underwriting Agreement with Natexis Bleichroeder Inc. ("Natexis") providing for the issuance and sale of up to 23,000,000 shares of common stock. Pursuant to the terms of the Underwriting Agreement, the Agency Agreement between the Company and Natexis dated September 30, 2003 was terminated. Item 7. Financial Statements and Exhibits. EXHIBIT NO. DESCRIPTION ----------- ----------- 99.1 Underwriting Agreement, dated October 16, 2003, by and between Genelabs Technologies, Inc. and Natexis Bleichroeder Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2003 GENELABS TECHNOLOGIES, INC. By: /s/ James A. D. Smith ------------------------------- Name: James A. D. Smith Title: President EXHIBIT INDEX EXHIBIT NO. DESCRIPTION ----------- ----------- 99.1 Underwriting Agreement, dated October 16, 2003, by and between Genelabs Technologies, Inc. and Natexis Bleichroeder Inc.